An analyst recently emphasized ASP’s potential to reduce Western dependence on Russia’s uranium supply chain, while highlighting the company’s innovative enrichment technology
If gains hold, the stock could be on for a record close as well as its best day ever.
The agreement outlines plans for constructing a uranium enrichment facility to produce High Assay Low-Enriched Uranium (HALEU) for future supply to TerraPower, a customer of Quantum Leap Energy (QLE).
The announcement quickly made ASPI one of the top 5 trending tickers on Stocktwits.
Earlier in October, Canaccord Genuity analyst George Gianarikas reaffirmed a ‘Buy’ rating on ASPI, setting a price target of $4.50 — which the stock has crossed already.
Gianarikas emphasized ASP’s potential to reduce Western dependence on Russia’s uranium supply chain, while highlighting the company’s innovative enrichment technology, which may advance nuclear medicine and semiconductor technology markets.
ASP’s recent early production of laser-enriched ytterbium-176 marks a crucial milestone, anticipated to add approximately $20 million in annual revenue, according to the brokerage.
ASP’s quantum enrichment technology not only validates its cutting-edge approach but also positions the company as a key player in the HALEU supply chain, which is critical to advanced nuclear fuel development.
These developments are significant because technology giants are increasingly turning to nuclear energy to power the data centers that train and run the large artificial intelligence models behind today’s generative AI applications.
ASP Isotope points out the rising demand for isotopes like Silicon-28 for quantum computing, Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for emerging healthcare applications, and Chlorine-37, Lithium-6, Lithium-7, and Uranium-235 for green energy initiatives.
So far in 2024, ASP stock has more than tripled, far outpacing the benchmark S&P 500 and Nasdaq indices.
For updates and corrections, email [email protected]
Read next: Eli Lilly Stock Slides Pre-Market On Weight-Loss Drug Sales Miss, But Retail Eyes Buying Opportunity
